.Pharmacolibrary.Drugs.ATC.D.D11AH10 .Pharmacolibrary.Drugs.ATC.D.D11AH10| name: | Lebrikizumab |
| ATC code: | D11AH10 | route: | subcutaneous |
| n-compartments | 2 |
Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine involved in the pathogenesis of atopic dermatitis and other inflammatory conditions. It is used primarily in the treatment of moderate-to-severe atopic dermatitis and is in clinical use and ongoing trials for this purpose. It is approved for use in several regions.
Pharmacokinetic parameters estimated for healthy adult subjects and patients with moderate-to-severe atopic dermatitis, based on population PK modeling.
Noonan, M, et al., & Matthews, JG (2013). Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. The Journal of allergy and clinical immunology 132(3) 567–574.e12. DOI:10.1016/j.jaci.2013.03.051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23726041